Most hepatocellular carcinomas (HCCs) arise in the context of chronic liver disease and/or cirrhosis. Thus, chemoprevention in individuals at risk represents an important but yet unproven approach. In this study, we investigated the ability of microRNA (miRNA)-based molecules to prevent liver cancer development in a cirrhotic model. To this end, we developed a mouse model able to recapitulate the natural progression from fibrosis to HCC, and then we tested the prophylactic activity of an miRNA-based approach in the model. The experiments were carried out in the TG221 transgenic mouse, characterized by the overexpression of miR-221 in the liver and predisposed to the development of liver tumors. TG221 as well as wild-type mice were exposed to the hepatotoxin carbon tetrachloride (CCl4) to induce chronic liver damage. All mice developed liver cirrhosis, but only TG221 mice developed nodular lesions in 100% of cases within 6 months of age. The spectrum of lesions ranged from dysplastic foci to carcinomas. To investigate miRNA-based prophylactic approaches, anti-miR-221 oligonucleotides or miR-199a-3p mimics were administered to TG221 CCl4-treated mice. Compared to control animals, a significant reduction in number, size, and, most significantly, malignant phenotype of liver nodules was observed, thus demonstrating an important prophylactic action of miRNA-based molecules. In summary, in this article, we not only report a simple model of liver cancer in a cirrhotic background but also provide evidence for a potential miRNA-based approach to reduce the risk of HCC development.

MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer / Callegari, E.; Domenicali, M.; Shankaraiah, R. C.; D'Abundo, L.; Guerriero, P.; Giannone, F.; Baldassarre, M.; Bassi, C.; Elamin, B. K.; Zagatti, B.; Ferracin, M.; Fornari, F.; Altavilla, G.; Blandamura, S.; Silini, E. M.; Gramantieri, L.; Sabbioni, S.; Negrini, M.. - In: MOLECULAR THERAPY NUCLEIC ACIDS. - ISSN 2162-2531. - 14:(2019), pp. 239-250. [10.1016/j.omtn.2018.11.018]

MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer

Callegari E.;Bassi C.;Silini E. M.;Sabbioni S.;
2019-01-01

Abstract

Most hepatocellular carcinomas (HCCs) arise in the context of chronic liver disease and/or cirrhosis. Thus, chemoprevention in individuals at risk represents an important but yet unproven approach. In this study, we investigated the ability of microRNA (miRNA)-based molecules to prevent liver cancer development in a cirrhotic model. To this end, we developed a mouse model able to recapitulate the natural progression from fibrosis to HCC, and then we tested the prophylactic activity of an miRNA-based approach in the model. The experiments were carried out in the TG221 transgenic mouse, characterized by the overexpression of miR-221 in the liver and predisposed to the development of liver tumors. TG221 as well as wild-type mice were exposed to the hepatotoxin carbon tetrachloride (CCl4) to induce chronic liver damage. All mice developed liver cirrhosis, but only TG221 mice developed nodular lesions in 100% of cases within 6 months of age. The spectrum of lesions ranged from dysplastic foci to carcinomas. To investigate miRNA-based prophylactic approaches, anti-miR-221 oligonucleotides or miR-199a-3p mimics were administered to TG221 CCl4-treated mice. Compared to control animals, a significant reduction in number, size, and, most significantly, malignant phenotype of liver nodules was observed, thus demonstrating an important prophylactic action of miRNA-based molecules. In summary, in this article, we not only report a simple model of liver cancer in a cirrhotic background but also provide evidence for a potential miRNA-based approach to reduce the risk of HCC development.
2019
MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer / Callegari, E.; Domenicali, M.; Shankaraiah, R. C.; D'Abundo, L.; Guerriero, P.; Giannone, F.; Baldassarre, M.; Bassi, C.; Elamin, B. K.; Zagatti, B.; Ferracin, M.; Fornari, F.; Altavilla, G.; Blandamura, S.; Silini, E. M.; Gramantieri, L.; Sabbioni, S.; Negrini, M.. - In: MOLECULAR THERAPY NUCLEIC ACIDS. - ISSN 2162-2531. - 14:(2019), pp. 239-250. [10.1016/j.omtn.2018.11.018]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2867244
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 15
social impact